NRx Pharmaceuticals' subsidiary selected by DARPA for negotiation of potential award for SPARC-TMS trial

NRX Pharmaceuticals, Inc.

NRX Defense Systems received DARPA letter selecting its proposal for negotiation of a potential award for SPARC-TMS phase 2/3 trial.
Trial combines robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.
NRX-101 previously received FDA Breakthrough Therapy Designation; trial approved by FDA and posted on ClinicalTrials.gov (NCT07227103).
Study sites include Harvard McLean Hospital, HOPE Therapeutics clinics, and Walter Reed National Military Medical Center.
Selection does not constitute a final award; subject to successful negotiation of definitive terms with DARPA/DSO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.